IDEXX Laboratories, Inc. $IDXX Stock: Ritholtz Wealth Management Reduces Stake

Ritholtz Wealth Management lessened its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report) by 16.7% during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 5,305 shares of the company’s stock after selling 1,061 shares during the quarter. Ritholtz Wealth Management’s holdings in IDEXX Laboratories were worth $2,770,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in IDXX. J.Safra Asset Management Corp bought a new position in IDEXX Laboratories in the second quarter valued at about $25,000. Elevation Wealth Partners LLC raised its holdings in IDEXX Laboratories by 188.2% during the 2nd quarter. Elevation Wealth Partners LLC now owns 49 shares of the company’s stock worth $26,000 after purchasing an additional 32 shares during the last quarter. Pension & Wealth Management Advisors Inc. bought a new stake in IDEXX Laboratories during the 3rd quarter worth about $29,000. Arlington Trust Co LLC lifted its position in IDEXX Laboratories by 46.3% during the 2nd quarter. Arlington Trust Co LLC now owns 60 shares of the company’s stock valued at $32,000 after purchasing an additional 19 shares during the period. Finally, Bell Investment Advisors Inc lifted its position in IDEXX Laboratories by 45.5% during the 3rd quarter. Bell Investment Advisors Inc now owns 64 shares of the company’s stock valued at $33,000 after purchasing an additional 20 shares during the period. Institutional investors and hedge funds own 87.84% of the company’s stock.

Insiders Place Their Bets

In other IDEXX Laboratories news, insider Jonathan Mazelsky sold 25,140 shares of the company’s stock in a transaction that occurred on Wednesday, November 4th. The shares were sold at an average price of $703.19, for a total value of $17,678,196.60. Following the completion of the sale, the insider owned 83,803 shares of the company’s stock, valued at approximately $58,929,431.57. This represents a 23.08% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sharon E. Underberg sold 8,906 shares of the stock in a transaction on Wednesday, November 4th. The stock was sold at an average price of $688.59, for a total transaction of $6,132,582.54. Following the completion of the sale, the executive vice president owned 7,169 shares in the company, valued at approximately $4,936,501.71. This trade represents a 55.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 41,428 shares of company stock worth $28,567,934 over the last ninety days. Company insiders own 0.79% of the company’s stock.

Analyst Upgrades and Downgrades

IDXX has been the topic of several recent research reports. The Goldman Sachs Group started coverage on shares of IDEXX Laboratories in a research note on Friday, October 16th. They issued a “buy” rating and a $740.00 target price on the stock. KeyCorp started coverage on shares of IDEXX Laboratories in a research note on Monday, October 12th. They set a “sector weight” rating for the company. UBS Group boosted their price target on shares of IDEXX Laboratories from $627.00 to $700.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 3rd. BTIG Research dropped coverage on shares of IDEXX Laboratories in a report on Friday, October 30th. They issued a “buy” rating on the stock. Finally, Jefferies Financial Group reduced their price objective on shares of IDEXX Laboratories from $795.00 to $705.00 and set a “buy” rating on the stock in a research note on Tuesday, October 20th. Seven research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $717.27.

Check Out Our Latest Stock Analysis on IDEXX Laboratories

IDEXX Laboratories Stock Performance

NASDAQ:IDXX opened at $704.23 on Monday. IDEXX Laboratories, Inc. has a 1-year low of $500.61 and a 1-year high of $769.98. The business’s 50-day moving average price is $562.41 and its two-hundred day moving average price is $573.52. The company has a current ratio of 1.19, a quick ratio of 0.88 and a debt-to-equity ratio of 0.16. The firm has a market capitalization of $55.48 billion, a price-to-earnings ratio of 47.49 and a beta of 1.55.

IDEXX Laboratories (NASDAQ:IDXX – Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.71 by $0.25. The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.19 billion. IDEXX Laboratories had a return on equity of 71.04% and a net margin of 25.36%. The company’s revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the business earned $3.22 earnings per share. On average, equities analysts expect that IDEXX Laboratories, Inc. will post 15.05 earnings per share for the current year.

IDEXX Laboratories Profile

(Free Report)

IDEXX Laboratories develops and sells diagnostic, technology and software products for veterinary, livestock and water-testing markets. Its veterinary offerings include in-clinic diagnostic instruments and tests, reference laboratory services, digital imaging and practice-management software that help veterinary professionals assess animal health and manage their practices. The company also provides diagnostic tests and related services for livestock and poultry, as well as products used to monitor water quality.

See Also

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX – Free Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.